Skip to content
    Clinical Trials

    Alectinib Yields 42% Major Pathologic Response in Stage III ALK-Positive NSCLC

    Leonetti et alJournal of clinical oncology : official journal of the American Society of Clinical Oncology

    Alectinib Yields 42% Major Pathologic Response in Stage III ALK-Positive NSCLC
    Stage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease with no single definitive therapeutic approach, and the clinical utility of neoadjuvant tyrosine kinase inhibitors in stage III ALK-positive disease has remained uncharacterized.
    Between May 2021 and July 2024, the trial enrolled 33 patients. Baseline characteristics included a median age of 62 years (range, 33–79), 70% female, 52% never smokers, 64% with clinical stage IIIA, and 36% with clinical stage IIIB disease. The therapeutic protocol consisted of neoadjuvant alectinib at 600 mg twice daily for 8 weeks, followed by surgical resection and up to 96 weeks of adjuvant alectinib. The primary end point was major pathologic response (MPR; defined as ≤10% residual viable tumor cells) assessed by blinded independent central review. Key secondary end points included pathologic complete response (pCR), objective response rate (ORR), event-free survival (EFS), disease-free survival (DFS), overall survival (OS), and safety.
    All 33 patients completed neoadjuvant alectinib, and 28 patients (85%) proceeded to surgery, with lobectomy performed in 75% of operations. Complete surgical clearance with R0 resection was achieved in 24 patients (86% of surgical cases). The primary end point was met, with MPR observed in 14 patients (42%; 95% CI, 26 to 61), which included four patients (12%; 95% CI, 3 to 28) who attained a pCR. The overall ORR was 67%. Adjuvant alectinib was initiated in 26 patients (79%).
    Safety analyses revealed grade ≥3 adverse events in 9% of patients during the neoadjuvant phase and in 27% during adjuvant therapy. Over a median follow-up duration of 26.8 months, median EFS, DFS, and OS were not reached, and six patients (18%) developed disease recurrence. The study authors concluded that ALNEO met its primary end point, suggesting that perioperative alectinib is a feasible and active treatment strategy in potentially resectable stage III ALK-positive NSCLC.

    Key Takeaways

    • Neoadjuvant alectinib achieved a major pathologic response rate of 42% (95% CI, 26 to 61) by blinded independent central review, with a 12% pathologic complete response rate (95% CI, 3 to 28) and an objective response rate of 67%.
    • Among enrolled patients, 85% underwent surgical resection—most commonly lobectomy (75%)—and R0 resection was attained in 86% of those who had surgery.
    • Grade ≥3 adverse events occurred in 9% of patients during neoadjuvant treatment and 27% during adjuvant treatment, while median event-free survival, disease-free survival, and overall survival were not reached at a median follow-up of 26.8 months.
    Read the original sourceJournal of clinical oncology : official journal of the American Society of Clinical Oncology